文献速递脑血管病

Xa因子抑制剂相关脑出血:andexanet alfa与常规治疗的比较

Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care.
PubMed 文献 · Stroke · 2021-10-14

本研究比较ANNEXA-4试验中接受andexanet alfa治疗与RETRACE-II队列中接受常规治疗(主要为凝血酶原复合物)的Xa因子抑制剂相关非创伤性颅内出血患者。结果显示andexanet alfa组血肿扩大率显著低于常规治疗组(14% vs 36%,调整相对风险0.40,95%CI 0.20-0.78,P=0.005),但住院死亡率和功能结局无显著差异。

要点

  • andexanet alfa与Xa因子抑制剂相关ICH患者血肿扩大率降低相关。
  • 血肿扩大率:andexanet alfa组14%,常规治疗组36%,调整RR 0.40。
  • 住院死亡率和功能结局两组无统计学显著差异。

核心结论

  • 与常规治疗相比,andexanet alfa与Xa因子抑制剂相关非创伤性ICH患者血肿扩大率降低相关,但未转化为临床结局的显著改善。

研究设计与样本

  • 数据来自多中心前瞻性单臂ANNEXA-4试验和多中心观察性队列RETRACE-II,共纳入182例患者(andexanet alfa组85例,常规治疗组97例)。
  • 纳入标准为入院18小时内正在服用阿哌沙班或利伐沙班的非创伤性ICH患者,排除继发性ICH或不符合ANNEXA-4试验纳入标准者。
  • 采用逆概率治疗加权调整基线合并症和ICH严重程度。

主要发现

  • 血肿扩大(定义为相对增加≥35%)发生在andexanet alfa组11/80例(14%)和常规治疗组21/67例(36%)(调整相对风险0.40,95%CI 0.20-0.78;P=0.005)。
  • 平均总体血肿体积变化减少7 mL。
  • 住院死亡率和功能结局在两组间无统计学显著差异。
  • 仅纳入接受凝血酶原复合物的常规治疗患者的敏感性分析结果一致。

关键数值与推荐

  • 血肿扩大定义为相对增加≥35%。
  • 血肿扩大评估基于基线影像后36小时内完成的CT扫描。
  • 主要结局为血肿扩大率,次要结局包括平均绝对血肿体积变化、住院死亡率和功能结局。

临床怎么用

  • 对于Xa因子抑制剂相关非创伤性ICH患者,andexanet alfa可能有助于限制血肿扩大。
  • 但当前证据未显示andexanet alfa较常规治疗显著改善住院死亡率或功能结局。
  • 需开展对比试验以确认限制血肿扩大的获益,并探索不同亚组及治疗时机的临床结局。

局限性

  • 比较基于单臂试验与观察性队列,非随机对照设计。
  • 样本量有限(共182例),可能不足以检测临床结局的显著差异。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: It is unestablished whether andexanet alfa, compared with guideline-based usual care including prothrombin complex concentrates, is associated with reduced hematoma expansion (HE) and mortality in patients with factor-Xa inhibitor-related intracerebral hemorrhage (ICH). We compared the occurrence of HE and clinical outcomes in patients treated either with andexanet alfa or with usual care during the acute phase of factor-Xa inhibitor-related ICH. METHODS: Data were extracted from the multicenter, prospective, single-arm ANNEXA-4 trial (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) and a multicenter observational cohort study, RETRACE-II (German-Wide Multicenter Analysis of Oral Anticoagulant-Associated Intracerebral Hemorrhage - Part Two). HE was based on computed tomography scans performed within 36 hours from baseline imaging. Inverse probability of treatment weighting was performed to adjust for baseline comorbidities and ICH severity. Patients presenting with atraumatic ICH while receiving apixaban or rivaroxaban within 18 hours of admission were included. Patients with secondary ICH or not fulfilling the inclusion criteria for the ANNEXA-4 trial were excluded. We compared ANNEXA-4 patients, who received andexanet alfa for hemostatic treatment, with RETRACE-II patients who were treated with usual care, primarily administration of prothrombin complex concentrates. Primary outcome was rate of HE defined as relative increase of ≥35%. Secondary outcomes comprised mean absolute change in hematoma volume, as well as in-hospital mortality and functional outcome. RESULTS: Overall, 182 patients with factor-Xa inhibitor-related ICH (85 receiving andexanet alfa versus 97 receiving usual care) were selected for analysis. There were no relevant differences regarding demographic or clinical characteristics between both groups. HE occurred in 11 of 80 (14%) andexanet alfa patients compared with 21 of 67 (36%) usual care patients (adjusted relative risk, 0.40 [95% CI, 0.20-0.78]; P=0.005), with a reduction in mean overall hematoma volume change of 7 mL. There were no statistically significant differences among in-hospital mortality or functional outcomes. Sensitivity analysis including only usual care patients receiving prothrombin complex concentrates demonstrated consistent results. CONCLUSIONS: As compared with usual care, andexanet alfa was associated with a lower rate of HE in atraumatic factor-Xa inhibitor-related ICH, however, without translating into significantly improved clinical outcomes. A comparative trial is needed to confirm the benefit on limiting HE and to explore clinical outcomes across patient subgroups and by time to treatment. Registration: URL: https://clinicaltrials.gov; Unique identifier: NCT02329327 and NCT03093233.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Huttner HB, Gerner ST, Kuramatsu JB, et al. Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. Stroke. 2021. PMID: 34645283. doi:10.1161/STROKEAHA.121.034572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。